Regorafenib is an oral MKI affecting vasculature and tumor microenvironment with targeting of specific kinase proteins (VEGFR1,2,3, PDGFR, FGFR, KIT, BRAF, and RET) [38]. This evidence concerns the gene RET and neoplasm.